Phio Pharmaceuticals (PHIO) Presents At Biotech Showcase 2020 - Slideshow

INTASYL™ Technology and its Advantages - Phio Pharmaceuticals utilizes a proprietary self-delivering RNAi platform called INTASYL™ for immuno-oncology therapeutics[5, 8] - INTASYL™ technology enhances immune effector cells and reprograms the tumor microenvironment (TME) without genetic modification, offering a cheaper, easier, and safer approach compared to other methods[4, 5, 19] - INTASYL™ achieves efficient cellular uptake and potent, long-lasting intracellular RNAi activity, making it more resistant to nuclease degradation and reducing immune side effects compared to classic siRNA[13] - INTASYL™ demonstrates superior cellular uptake, with >700x uptake compared to competitor RNAi, and superior silencing, with >13x silencing compared to competitor RNAi[30, 31] Pipeline and Lead Product Candidates - The company's pipeline includes several immuno-oncology therapeutics based on the INTASYL™ platform, targeting PD-1, TIGIT, and PD-L1 inhibition in both ACT and TME applications[36] - PH-762, the lead product candidate, is being developed for PD-1 inhibition in ACT and direct TME administration, with late preclinical development focused on melanoma and other indications[38, 41] - PH-762 demonstrates effective PD-1 receptor silencing in primary human T cells, with IC50 values of 034 μM for mRNA knockdown and 027-036 μM for protein expression reduction[46, 48, 49] - PH-804, another product candidate, targets TIGIT inhibition in ACT and TME applications, showing powerful, dose-dependent, and persistent TIGIT mRNA silencing in human T cells and NK cells[55, 62, 65] Financial Status and Upcoming Milestones - As of December 31, 2019, Phio Pharmaceuticals had approximately $69 million in cash, with a burn rate of $20 million per quarter, providing a cash runway into Q3 2020[83] - Upcoming milestones include data releases on PH-762 and new discovery targets, in vivo study results for PH-804, and potential partnering for INTASYL™ in ACT[86, 87] - The company forecasts a >$12 billion market in 2026 for metastatic melanoma therapies, highlighting the unmet medical need and potential for PH-762[81]